Hudson Bay Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Hudson Bay Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.55M	Sell	955,000 -13,940	-1%	-$34.4K	0.01%	758
2026 Q1	$2.29M	Buy	968,940 +243,940	+34%	+$622K	0.01%	736
2025 Q4	$1.53M	Sell	725,000 -4	-0%	-$8	0.01%	748
2025 Q3	$1.24M	Sell	725,004 -100,000	-12%	-$138K	﹤0.01%	829
2025 Q2	$957K	Buy	825,004 +55,004	+7%	+$59.1K	﹤0.01%	968
2025 Q1	$847K	Buy	770,000 +55,000	+8%	+$78.6K	﹤0.01%	952
2024 Q4	$1.23M	Buy	715,000 +79,000	+12%	+$190K	﹤0.01%	717
2024 Q3	$1.58M	Sell	636,000 -34,000	-5%	-$92.2K	0.01%	599
2024 Q2	$1.62M	Buy	670,000 +110,000	+20%	+$350K	0.01%	548
2024 Q1	$2.27M	Sell	560,000 -4,400	-0.8%	-$16.6K	0.01%	432
2023 Q4	$2.17M	Buy	564,400 +39,400	+8%	+$117K	0.01%	436
2023 Q3	$2.18M	Buy	525,000 +130,000	+33%	+$803K	0.02%	460
2023 Q2	$1.9M	Buy	395,000 +38,000	+11%	+$182K	0.01%	513
2023 Q1	$1.45M	Buy	357,000 +117,000	+49%	+$611K	0.01%	557
2022 Q4	$1.3M	Buy	+240,000	New	+$1.61M	0.01%	665

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Hudson Bay Capital Management's ABOS Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Acumen Pharmaceuticals (ABOS) stake by 1.4% in Q2 2026, selling an estimated $34.4K and leaving 955,000 shares worth $2.55M. The position accounts for 0.01% of the portfolio, ranked #758.

Hudson Bay Capital Management first reported a position in ABOS in Q4 2022 and has held it in 15 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Hudson Bay Capital Management held 955,000 shares of Acumen Pharmaceuticals worth $2.55M as of Q2 2026.
Hudson Bay Capital Management sold 13,940 Acumen Pharmaceuticals shares in Q2 2026, an estimated $34.4K.
Acumen Pharmaceuticals made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #758 holding.
Hudson Bay Capital Management first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.